Skip to content

Auditory Brainstem Implant System Pre-Market Clinical Trial

Prospective, multi-center, open-label, single-arm clinical trial: safety and efficacy evaluation of auditory brainstem implantation system in children with non-syndromic and non-tumor induced prelingual hearing loss

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054208
Enrollment
Unknown
Registered
2021-12-11
Start date
2022-01-03
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-symdromic and non-tumor induced prelingual hearing loss

Interventions

Auditory Brainstem Implantation group:No

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Prelingual hearing loss patients aged 1-6 years (excluding 6 years old); 2. Non-syndromic hearing loss; 3. Non-tumor related hearing loss; 4. Patients with inner ear malformations unable to undergo cochlear implantation (michel deformity, rudimentary otocyst, cochlear aplasia, etc.); or severe inner ear malformations (cochlear malformation, cochlear dysplasia, common cavity, IP-I) with no auditory and speech development after cochlear implantation (>= 12 months); 5. Meet audiology evaluation and imaging evaluation criteria; 6. No surgical contraindications and other severe congenital malformations/complications; 7. Consist of conditions for hearing and speech rehabilitation education; 8. Agree to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to the implant material; 2. Intellectual disability; 3. Mental illness; 4. Unable to cooperate with audiology assessment and language training; 5. Brain tissue structure abnormality that affects implantation surgery or postoperative assessments; 6. Patients who need to undergo follow-up radiotherapy at the brain stem; 7. Poor general health condition and unable to undergo surgery; 8. Uncontrollable epilepsy; 9. Unsuitable for inclusion after evaluation of investigator.

Design outcomes

Primary

MeasureTime frame
Total efficacy rate;

Secondary

MeasureTime frame
Speech recognition evaluation;Electrophysiological assessment;Electrode placement evaluation;Device condition;Adverse event rate;

Countries

China

Contacts

Public ContactWu Hao

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

lvmt801@163.com+86 13552564506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026